**Trader consensus strongly favors no hantavirus vaccine licensed by the end of 2026, driven by the fact that all candidates remain in preclinical or early clinical stages.** Multiple mRNA constructs, including single-dose formulations from UTMB that achieved 100% protection against Andes virus in Syrian hamster models, and the Moderna–Korea University collaboration, have shown immunogenicity in animals but have not entered human trials. DNA vaccines against Hantaan and Puumala viruses completed Phase 1 with neutralizing antibodies induced and advanced to Phase 2a, while an MVA-based candidate finished UK Phase 1 enrollment in April 2026. No Phase 3 efficacy studies are underway, and regulatory pathways for rare zoonoses require extensive safety and field data. The May–June 2026 MV Hondius outbreak heightened visibility and prompted additional preclinical work, yet standard development timelines—spanning years even with mRNA platforms—make 2026 approval improbable without unprecedented funding acceleration.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% probabilità
$131,479 Vol.
$131,479 Vol.
31 dic 2026
6% probabilità
$131,479 Vol.
$131,479 Vol.
31 dic 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus strongly favors no hantavirus vaccine licensed by the end of 2026, driven by the fact that all candidates remain in preclinical or early clinical stages.** Multiple mRNA constructs, including single-dose formulations from UTMB that achieved 100% protection against Andes virus in Syrian hamster models, and the Moderna–Korea University collaboration, have shown immunogenicity in animals but have not entered human trials. DNA vaccines against Hantaan and Puumala viruses completed Phase 1 with neutralizing antibodies induced and advanced to Phase 2a, while an MVA-based candidate finished UK Phase 1 enrollment in April 2026. No Phase 3 efficacy studies are underway, and regulatory pathways for rare zoonoses require extensive safety and field data. The May–June 2026 MV Hondius outbreak heightened visibility and prompted additional preclinical work, yet standard development timelines—spanning years even with mRNA platforms—make 2026 approval improbable without unprecedented funding acceleration.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Mercato aperto: May 4, 2026, 10:39 AM ET
Volume
$131,479Data di fine
1 gen 2027Mercato aperto
May 4, 2026, 10:39 AM ETRisolutore
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus strongly favors no hantavirus vaccine licensed by the end of 2026, driven by the fact that all candidates remain in preclinical or early clinical stages.** Multiple mRNA constructs, including single-dose formulations from UTMB that achieved 100% protection against Andes virus in Syrian hamster models, and the Moderna–Korea University collaboration, have shown immunogenicity in animals but have not entered human trials. DNA vaccines against Hantaan and Puumala viruses completed Phase 1 with neutralizing antibodies induced and advanced to Phase 2a, while an MVA-based candidate finished UK Phase 1 enrollment in April 2026. No Phase 3 efficacy studies are underway, and regulatory pathways for rare zoonoses require extensive safety and field data. The May–June 2026 MV Hondius outbreak heightened visibility and prompted additional preclinical work, yet standard development timelines—spanning years even with mRNA platforms—make 2026 approval improbable without unprecedented funding acceleration.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$131,479Data di fine
1 gen 2027Mercato aperto
May 4, 2026, 10:39 AM ETRisolutore
0x65070BE91...**Trader consensus strongly favors no hantavirus vaccine licensed by the end of 2026, driven by the fact that all candidates remain in preclinical or early clinical stages.** Multiple mRNA constructs, including single-dose formulations from UTMB that achieved 100% protection against Andes virus in Syrian hamster models, and the Moderna–Korea University collaboration, have shown immunogenicity in animals but have not entered human trials. DNA vaccines against Hantaan and Puumala viruses completed Phase 1 with neutralizing antibodies induced and advanced to Phase 2a, while an MVA-based candidate finished UK Phase 1 enrollment in April 2026. No Phase 3 efficacy studies are underway, and regulatory pathways for rare zoonoses require extensive safety and field data. The May–June 2026 MV Hondius outbreak heightened visibility and prompted additional preclinical work, yet standard development timelines—spanning years even with mRNA platforms—make 2026 approval improbable without unprecedented funding acceleration.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti